Evidence map›Paper›PMID 42022569›Full record

ArticleFrontiers in pharmacology2026

Dual mechanisms of a purified root extract of

Tingting Jin, Ruoling Xu, Zhuoxin Jiang, Juncheng Ma, Ning Li

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tingting Jin *Anhui Key Laboratory of Bioactivity of Natural Products, School of Pharmacy, Anhui Medical University, Hefei, China.
Ruoling Xu *Anhui Key Laboratory of Bioactivity of Natural Products, School of Pharmacy, Anhui Medical University, Hefei, China.
Zhuoxin JiangAnhui Key Laboratory of Bioactivity of Natural Products, School of Pharmacy, Anhui Medical University, Hefei, China.
Juncheng MaAnhui Key Laboratory of Bioactivity of Natural Products, School of Pharmacy, Anhui Medical University, Hefei, China.
Ning LiAnhui Key Laboratory of Bioactivity of Natural Products, School of Pharmacy, Anhui Medical University, Hefei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Hyperuricemia (HUA), characterized by persistently elevated serum uric acid (UA), represents a growing global public-health concern. Current urate-lowering medications are often associated with hepatotoxicity and nephrotoxicity, highlighting the urgent need for safer, food-derived alternatives. Methods: A macroporous resin-purified fraction (PLE-2) from Results: Discussion: PLE-2 demonstrates potent dual action on UA synthesis and excretion with notable nephroprotective effects, positioning the purified fraction as a promising functional food metabolite for preventing and ameliorating HUA.

Indexed as

adenosine deaminasehyperuricemiaPaeonia lactiflora Pallrenal transporter proteinuric acidxanthine oxidase

Identifiers

PMID42022569
PMCPMC13095781

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.